“As a gynecologic pathologist and Chair of a large Department of Pathology in a major academic university, I am well aware of the importance, especially for patients with ovarian cancer, and notorious challenges, of HRD molecular testing. HRD testing is much more difficult and complex than many other genomic tests currently in clinical use. The oncology community, as well as most large academic medical centers, must rely on send-outs, which are expensive, require a lot of tissue, have slower turn-around-times, and are subject to higher test failure rates than other molecular tests.

Dr. Alexandrov and his colleagues at Acurion have picked absolutely the right molecular test to improve upon with their innovative approach, replace with an AI test AI frameworks an approach that unlocks the power of routine H&E stained slides to detect HRD, as a welcome improvement on current workflows. I see our patients benefitting from this new approach that will greatly increase the value and importance of our pathology reports.”